Asthma Clinical Trial
Official title:
Evaluation of the Lungs of Individuals With Lung Disease With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing and Bronchial Wall Biopsy
The purpose of this protocol is to obtain biologic materials from the blood and lungs from patients with lung disease in order to develop an understanding of the etiology and pathogenesis of these disorders. General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) patients with diseases of organs with known association with lung disease.
Patients will undergo a general medical evaluation by a pulmonary physician (and consultants
as appropriate for other organs). The typical routine medical studies to be carried out may
include: chest X-ray (posterior-anterior and lateral), non-contrast high resolution CT scan
of the chest, pulmonary function tests, electrocardiogram, echocardiogram, general
hematologic studies, general serologic studies, /immunologic studies, biochemical analyses
(including carboxyhemoglobin to measure blood carbon monoxide levels in order to accurately
evaluate the diffusion capacity in individuals who smoke since smoking increases the blood
levels of carbon monoxide), alcohol blood test, urinalysis, urine chemistries (including
blood or urine nicotine and cotinine test to evaluate urine for active or passive exposure
to nicotine), blood or urine drug screening (to evaluate use of recreational drugs and/or
mood altering medications), pregnancy test (if applicable) and HIV serology. Also, a sweat
chloride and sweat rate test may be performed by the physician to evaluate participants with
a possible diagnosis of cystic fibrosis.
The study individual will undergo fiberoptic bronchoscopy with a combination of bronchial
brushing and/or bronchoalveolar lavage and/or bronchial wall biopsy. The primary factor for
determining if an individual will have bronchial alveolar lavages (BAL) and/or brushings
and/or biopsies is the particular lung disease affecting the individual. This will depend on
the known mechanism relevant to the pathogenesis of the particular disease. For example, in
individuals with asthma, the samples may include airway brushing and airway biopsies; in
contrast, in individuals with chronic obstructive pulmonary disease (COPD), sampling may
include airway brushings, airway biopsies, and bronchoalveolar lavage. Other determining
factors include: the amount of moderate sedation (if used) and the amount of analgesia used;
the maximal dosage of topical lidocaine that is allowed per procedure; allergic reactions to
any of the medications used in the procedures; and individual's tolerance to the procedure.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|